Project Grant R01CA292590
Award Date
6/4/25
Completion Date
5/31/30
Dollars Obligated
$663K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award for $716,314.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop novel therapeutics targeting FGFR2 alterations in gastroesophageal adenocarcinoma (GEA). The key products and services to be delivered include: Utilizing novel immune-competent mouse models of FGFR2-altered GEA to develop and test highly efficacious FGFR2 biparatopic antibodies (BIPABs) and FGFR2-targeted antibody-drug conjugates (ADCs), alone or in...
The federal Project Grant award K01CA297135 in the amount of $166,037.00 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) to the University of California, San Diego (UCSD) to conduct research on targeting the CDK4/6 pathway as an interception strategy for intraductal papillary mucinous neoplasms (IPMNs), which are common pancreatic cystic neoplasms that can progress to pancreatic ductal adenocarcinoma. The research aims to determine the impact of...
The National Cancer Institute awarded a 5-year, $655,306 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Regents of the University of California, San Francisco (UCSF) to develop a novel therapeutic strategy for treating isocitrate dehydrogenase (IDH)-mutant gliomas, a deadly form of brain cancer. The project aims to leverage the vulnerability of IDH-mutant gliomas to reactive metabolite accumulation by combining a potent glyoxalase 1 (GLO1) inhibitor with radiation therapy. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The $188,169 grant, awarded on March 10, 2025, will fund proof-of-concept studies to evaluate the biological activity and efficacy of this gene therapy approach in killing cancer cells through in vitro assays...
This $444,952 federal Project Grant award, titled "Exploring the Impact of Base Deaminase Deregulation on Precancer Evolution," was provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the University of California, San Diego (UC San Diego). The goal of this 5-year research project is to investigate how deregulation of the APOBEC3C and ADAR1 base deaminase enzymes drives the transformation of pre-leukemic stem cells (pre-LSCs) into more aggressive...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $670,904 to The Regents of the University of California, San Francisco (UCSF) to develop metabolic therapy and imaging for diffuse midline gliomas (DMGs), a devastating type of brain cancer in children. The research aims to identify and target the vulnerabilities induced by the H3K27M mutation that drives DMGs, specifically inhibiting the enzymes...
This National Cancer Institute (NCI) Project Grant award under the Cancer Treatment Research program (CFDA 93.395) provides $269,280 to Cold Spring Harbor Laboratory to develop a novel targeted approach for K-RAS(G12C) mutation-driven cancers. The project aims to create multifunctional prodrug molecules that can selectively bind to and degrade the K-RAS(G12C) oncogenic protein, while also releasing cytotoxic natural products to target multiple pathways concurrently. Key objectives include...
This federal Project Grant award of $552,763, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), supports research to assess the therapeutic potential of newly developed KAT6 inhibitors (KAT6Is) as monotherapy and in combination with targeted therapies for high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC). The research, conducted by The Trustees of the University of Pennsylvania, aims to characterize the epigenetic...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing the efficacy of KRAS inhibitor therapies for cancer treatment. The key focus is to identify synthetic lethal genes and resistance mechanisms that can be targeted to improve outcomes for patients with KRAS-mutated cancers, such as non-small cell lung cancer, colorectal cancer, and pancreatic cancer....
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $125,783 to The University of Texas M.D. Anderson Cancer Center to investigate the mechanisms driving the progression of advanced gastric adenocarcinoma (GAC), a form of stomach cancer. The research aims to uncover how the inactivation of the CDH1 gene, which is linked to the activation of SOX4 and EZH2, promotes GAC progression. The project will establish mouse organoid models to...